Evaluation of the combination of gemcitabine, carboplatin, and lactate dehydrogenase A inhibitor on malignant mesothelioma

References

• Bertin, B.; Zugman, M.; Schvartsman, G. The Current Treatment Landscape of Malignant Pleural Mesothelioma and Future Directions. Cancers. (Basel) 2023, 15, 5808. DOI: 10.3390/cancers15245808.
   PubMed Web of Science ®Google Scholar
• Karpes, J. B.; Shamavonian, R.; Dewhurst, S.; Cheng, E.; Wijayawardana, R.; Ahmadi, N.; Morris, D. L. Malignant Peritoneal Mesothelioma: An In-Depth and Up-to-Date Review of Pathogenesis, Diagnosis, Management and Future Directions. Cancers. (Basel) 2023, 15, 4704. DOI: 10.3390/cancers15194704.
   PubMed Web of Science ®Google Scholar
• Kusamura, S.; Baratti, D.; De Simone, M.; Pasqual, E. M.; Ansaloni, L.; Marrelli, D.; Robella, M.; Accarpio, F.; Valle, M.; Scaringi, S.; et al. Diagnostic and Therapeutic Pathway in Diffuse Malignant Peritoneal Mesothelioma. Cancers. (Basel) 2023, 15, 662. DOI: 10.3390/cancers15030662.
   PubMed Web of Science ®Google Scholar
• Iranzo, P.; Callejo, A.; Assaf, J. D.; Molina, G.; Lopez, D. E.; Garcia-Illescas, D.; Pardo, N.; Navarro, A.; Martinez-Marti, A.; Cedres, S.; et al. Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer. Front. Med. (Lausanne) 2022, 9, 875974. DOI: 10.3389/fmed.2022.875974.
   PubMed Web of Science ®Google Scholar
• Borea, F.; Franczak, M. A.; Garcia, M.; Perrino, M.; Cordua, N.; Smolenski, R. T.; Peters, G. J.; Dziadziuszko, R.; Santoro, A.; Zucali, P. A.; et al. Target Therapy in Malignant Pleural Mesothelioma: Hope or Mirage? Int. J. Mol. Sci. 2023, 24, 9165. DOI: 10.3390/ijms24119165.
   PubMed Web of Science ®Google Scholar
• Bergman, A. M.; Pinedo, H. M.; Peters, G. J. Determinants of Resistance to 2′,2′-Difluorodeoxycytidine (Gemcitabine). Drug Resist. Updat. 2002, 5, 19–33. DOI: 10.1016/S1368-7646(02)00002-X.
   PubMed Web of Science ®Google Scholar
• Bergman, A. M.; Ruiz van Haperen, V. W.; Veerman, G.; Kuiper, C. M.; Peters, G. J. Synergistic Interaction between Cisplatin and Gemcitabine in Vitro. Clin. Cancer Res. 1996, 2, 521–530.
   PubMed Web of Science ®Google Scholar
• Peters, G. J.; Van Moorsel, C. J. A.; Lakerveld, B.; Smid, K.; Noordhuis, P.; Comijn, E. C.; Weaver, D.; Willey, J. C.; Voorn, D.; Van der Vijgh, W. J. F.; et al. Effects of Gemcitabine on Cis-Platinum-DNA Adduct Formation and Repair in a Panel of Gemcitabine and Cisplatin-Sensitive or -Resistant Human Ovarian Cancer Cell Lines. Int. J. Oncol. 2006, 28, 237–244.
   PubMed Web of Science ®Google Scholar
• Maftouh, M.; Avan, A.; Sciarrillo, R.; Granchi, C.; Leon, L. G.; Rani, R.; Funel, N.; Smid, K.; Honeywell, R.; Boggi, U.; et al. Synergistic Interaction of Novel Lactate Dehydrogenase Inhibitors with Gemcitabine against Pancreatic Cancer Cells in Hypoxia. Br. J. Cancer 2014, 110, 172–182. DOI: 10.1038/bjc.2013.681.
   PubMed Web of Science ®Google Scholar
• Li Petri, G.; El Hassouni, B.; Sciarrillo, R.; Funel, N.; Mantini, G.; Zeeuw van der Laan, E. A.; Cascioferro, S.; Avan, A.; Zucali, P. A.; Zaffaroni, N.; et al. Impact of Hypoxia on Chemoresistance of Mesothelioma Mediated by the Proton-Coupled Folate Transporter, and Preclinical Activity of New Anti-LDH-A Compounds. Br. J. Cancer 2020, 123, 644–656. DOI: 10.1038/s41416-020-0912-9.
   PubMed Web of Science ®Google Scholar
• Giovannetti, E.; Leon, L. G.; Gómez, V. E.; Zucali, P. A.; Minutolo, F.; Peters, G. J. A Specific Inhibitor of Lactate Dehydrogenase Overcame the Resistance toward Gemcitabine in Hypoxic Mesothelioma Cells, and Modulated the Expression of the Human Equilibrative Transporter-1. Nucleosides. Nucleotides Nucleic Acids 2016, 35, 643–651. DOI: 10.1080/15257770.2016.1149193.
   PubMed Web of Science ®Google Scholar
• Franczak, M. A.; Krol, O.; Harasim, G.; Jedrzejewska, A.; Zaffaroni, N.; Granchi, C.; Minutolo, F.; Avan, A.; Giovannetti, E.; Smolenski, R. T.; et al. Metabolic Effects of New Glucose Transporter (GLUT-1) and Lactate Dehydrogenase-A (LDH-A) Inhibitors against Chemoresistant Malignant Mesothelioma. Int. J. Mol. Sci. 2023, 24, 7771. DOI: 10.3390/ijms24097771.
   PubMed Web of Science ®Google Scholar
• Keepers, Y. P.; Pizao, P. E.; Peters, G. J.; van Ark-Otte, J.; Winograd, B.; Pinedo, H. M. Comparison of the Sulforhodamine B Protein and Tetrazolium (MTT) Assays for in Vitro Chemosensitivity Testing. Eur. J. Cancer 1991, 27, 897–900. DOI: 10.1016/0277-5379(91)90142-Z.
   PubMed Web of Science ®Google Scholar
• Giovannetti, E.; Zucali, P. A.; Assaraf, Y. G.; Leon, L. G.; Smid, K.; Alecci, C.; Giancola, F.; Destro, A.; Gianoncelli, L.; Lorenzi, E.; et al. Preclinical Emergence of Vandetanib as a Potent Antitumour Agent in Mesothelioma: Molecular Mechanisms Underlying Its Synergistic Interaction with Pemetrexed and Carboplatin. Br. J. Cancer 2011, 105, 1542–1553. DOI: 10.1038/bjc.2011.400.
   PubMed Web of Science ®Google Scholar
• Favaretto, A. G.; Aversa, S. M. L.; Paccagnella, A.; Manzini, V. D. P.; Palmisano, V.; Oniga, F.; Stefani, M.; Rea, F.; Bortolotti, L.; Loreggian, L.; et al. Gemcitabine Combined with Carboplatin in Patients with Malignant Pleural Mesothelioma. Cancer 2003, 97, 2791–2797. DOI: 10.1002/cncr.11405.
   PubMed Web of Science ®Google Scholar
• Garcia-Carbonero, R.; Paz-Ares, L. Systemic Chemotherapy in the Management of Malignant Peritoneal Mesothelioma. Eur. J. Surg. Oncol. 2006, 32, 676–681. DOI: 10.1016/j.ejso.2006.03.009.
   PubMed Web of Science ®Google Scholar
• Dómine, M.; Casado, V.; Estévez, L. G.; León, A.; Martin, J. I.; Castillo, M.; Rubio, G.; Lobo, F. Gemcitabine and Carboplatin for Patients with Advanced Non-Small Cell Lung Cancer. Semin. Oncol. 2001, 28, 4–9.
   PubMed Web of Science ®Google Scholar
• Pfisterer, J.; Plante, M.; Vergote, I.; Du Bois, A.; Hirte, H.; Lacave, A. J.; Wagner, U.; Stähle, A.; Stuart, G.; Kimmig, R.; et al. Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J. Clin. Oncol. 2006, 24, 4699–4707. DOI: 10.1200/JCO.2006.06.0913.
   PubMed Web of Science ®Google Scholar
• Carles, J.; Nogué, M. Gemcitabine/Carboplatin in Advanced Urothelial Cancer. Semin. Oncol. 2001, 28, 19–24. DOI: 10.1053/sonc.2001.22537.
   PubMed Web of Science ®Google Scholar
• Fang, X.; Shu, L.; Chen, T.; Zhao, X.; Yang, L.; Dou, T.; Yang, L.; Li, X.; Feng, M. Organoids Derived from Patients Provide a New Opportunity for Research and Individualized Treatment of Malignant Peritoneal Mesothelioma. Mol. Cancer 2024, 23, 12. DOI: 10.1186/s12943-023-01901-z.
   PubMed Web of Science ®Google Scholar
• Palmer, A. C.; Chidley, C.; Sorger, P. K. A Curative Combination Cancer Therapy Achieves High Fractional Cell Killing through Low Cross-Resistance and Drug Additivity. Elife 2019, 8, e50036. DOI: 10.7554/eLife.50036.
   Web of Science ®Google Scholar
• EL Hassouni, B.; Mantini, G.; Li Petri, G.; Capula, M.; Boyd, L.; Weinstein, H. N. W.; Vallés-Marti, A.; Kouwenhoven, M. C. M.; Giovannetti, E.; Westerman, B. A.; et al. To Combine or Not Combine: Drug Interactions and Tools for Their Analysis. Reflections from the EORTC-PAMM Course on Preclinical and Early-Phase Clinical Pharmacology. Anticancer Res. 2019, 39, 3303–3309. DOI: 10.21873/anticanres.13472.
   PubMed Web of Science ®Google Scholar